nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—Vismodegib—Sulfasalazine—ankylosing spondylitis	0.602	1	CrCrCtD
Sorafenib—ABCC2—Sulfasalazine—ankylosing spondylitis	0.0286	0.103	CbGbCtD
Sorafenib—ABCG2—Sulfasalazine—ankylosing spondylitis	0.0259	0.0933	CbGbCtD
Sorafenib—ABCC4—Methotrexate—ankylosing spondylitis	0.0193	0.0696	CbGbCtD
Sorafenib—CYP3A5—Sulfasalazine—ankylosing spondylitis	0.0143	0.0517	CbGbCtD
Sorafenib—ABCC2—Dexamethasone—ankylosing spondylitis	0.0143	0.0515	CbGbCtD
Sorafenib—ABCG2—Dexamethasone—ankylosing spondylitis	0.0129	0.0466	CbGbCtD
Sorafenib—ABCB1—Methylprednisolone—ankylosing spondylitis	0.0123	0.0444	CbGbCtD
Sorafenib—ABCC2—Methotrexate—ankylosing spondylitis	0.0115	0.0414	CbGbCtD
Sorafenib—ABCG2—Methotrexate—ankylosing spondylitis	0.0104	0.0374	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Dexamethasone—ankylosing spondylitis	0.00953	0.0344	CbGbCtD
Sorafenib—CYP3A7—Dexamethasone—ankylosing spondylitis	0.00953	0.0344	CbGbCtD
Sorafenib—CYP2C19—Prednisone—ankylosing spondylitis	0.00924	0.0333	CbGbCtD
Sorafenib—CYP2B6—Dexamethasone—ankylosing spondylitis	0.00908	0.0327	CbGbCtD
Sorafenib—ABCB1—Betamethasone—ankylosing spondylitis	0.008	0.0289	CbGbCtD
Sorafenib—ABCB1—Prednisolone—ankylosing spondylitis	0.0079	0.0285	CbGbCtD
Sorafenib—ABCB1—Prednisone—ankylosing spondylitis	0.00746	0.0269	CbGbCtD
Sorafenib—CYP3A4—Methylprednisolone—ankylosing spondylitis	0.00737	0.0266	CbGbCtD
Sorafenib—CYP3A5—Dexamethasone—ankylosing spondylitis	0.00715	0.0258	CbGbCtD
Sorafenib—CYP2C8—Dexamethasone—ankylosing spondylitis	0.00688	0.0248	CbGbCtD
Sorafenib—CYP2C19—Dexamethasone—ankylosing spondylitis	0.00577	0.0208	CbGbCtD
Sorafenib—CYP3A4—Triamcinolone—ankylosing spondylitis	0.00559	0.0202	CbGbCtD
Sorafenib—CYP2C9—Dexamethasone—ankylosing spondylitis	0.0048	0.0173	CbGbCtD
Sorafenib—CYP3A4—Betamethasone—ankylosing spondylitis	0.00479	0.0173	CbGbCtD
Sorafenib—CYP3A4—Prednisolone—ankylosing spondylitis	0.00473	0.0171	CbGbCtD
Sorafenib—ABCB1—Dexamethasone—ankylosing spondylitis	0.00465	0.0168	CbGbCtD
Sorafenib—CYP3A4—Prednisone—ankylosing spondylitis	0.00447	0.0161	CbGbCtD
Sorafenib—CYP2D6—Dexamethasone—ankylosing spondylitis	0.00439	0.0158	CbGbCtD
Sorafenib—ABCB1—Methotrexate—ankylosing spondylitis	0.00374	0.0135	CbGbCtD
Sorafenib—CYP3A4—Dexamethasone—ankylosing spondylitis	0.00279	0.0101	CbGbCtD
Sorafenib—MUSK—tendon—ankylosing spondylitis	0.000224	0.151	CbGeAlD
Sorafenib—Mental disorder—Methylprednisolone—ankylosing spondylitis	0.000139	0.00208	CcSEcCtD
Sorafenib—Erythema—Triamcinolone—ankylosing spondylitis	0.000138	0.00208	CcSEcCtD
Sorafenib—Malnutrition—Methylprednisolone—ankylosing spondylitis	0.000138	0.00207	CcSEcCtD
Sorafenib—Erythema—Methylprednisolone—ankylosing spondylitis	0.000138	0.00207	CcSEcCtD
Sorafenib—Acute coronary syndrome—Prednisone—ankylosing spondylitis	0.000138	0.00207	CcSEcCtD
Sorafenib—Angioedema—Prednisolone—ankylosing spondylitis	0.000137	0.00206	CcSEcCtD
Sorafenib—Myocardial infarction—Prednisone—ankylosing spondylitis	0.000137	0.00206	CcSEcCtD
Sorafenib—Neuropathy peripheral—Prednisone—ankylosing spondylitis	0.000137	0.00206	CcSEcCtD
Sorafenib—Breast disorder—Methotrexate—ankylosing spondylitis	0.000137	0.00206	CcSEcCtD
Sorafenib—Toxic epidermal necrolysis—Methotrexate—ankylosing spondylitis	0.000137	0.00205	CcSEcCtD
Sorafenib—Dysgeusia—Triamcinolone—ankylosing spondylitis	0.000135	0.00203	CcSEcCtD
Sorafenib—Syncope—Prednisolone—ankylosing spondylitis	0.000135	0.00202	CcSEcCtD
Sorafenib—Loss of consciousness—Prednisolone—ankylosing spondylitis	0.000132	0.00198	CcSEcCtD
Sorafenib—Angiopathy—Dexamethasone—ankylosing spondylitis	0.000131	0.00196	CcSEcCtD
Sorafenib—Angiopathy—Betamethasone—ankylosing spondylitis	0.000131	0.00196	CcSEcCtD
Sorafenib—Hypertension—Prednisolone—ankylosing spondylitis	0.00013	0.00195	CcSEcCtD
Sorafenib—Arrhythmia—Dexamethasone—ankylosing spondylitis	0.000129	0.00193	CcSEcCtD
Sorafenib—Arrhythmia—Betamethasone—ankylosing spondylitis	0.000129	0.00193	CcSEcCtD
Sorafenib—Pancreatitis—Methotrexate—ankylosing spondylitis	0.000128	0.00193	CcSEcCtD
Sorafenib—Alopecia—Dexamethasone—ankylosing spondylitis	0.000127	0.00191	CcSEcCtD
Sorafenib—Alopecia—Betamethasone—ankylosing spondylitis	0.000127	0.00191	CcSEcCtD
Sorafenib—Angioedema—Triamcinolone—ankylosing spondylitis	0.000126	0.0019	CcSEcCtD
Sorafenib—Haemoglobin—Prednisone—ankylosing spondylitis	0.000126	0.00189	CcSEcCtD
Sorafenib—Angioedema—Methylprednisolone—ankylosing spondylitis	0.000126	0.00189	CcSEcCtD
Sorafenib—Abdominal discomfort—Methotrexate—ankylosing spondylitis	0.000126	0.00189	CcSEcCtD
Sorafenib—Haemorrhage—Prednisone—ankylosing spondylitis	0.000126	0.00188	CcSEcCtD
Sorafenib—Erythema—Dexamethasone—ankylosing spondylitis	0.000125	0.00188	CcSEcCtD
Sorafenib—Erythema—Betamethasone—ankylosing spondylitis	0.000125	0.00188	CcSEcCtD
Sorafenib—Syncope—Triamcinolone—ankylosing spondylitis	0.000124	0.00186	CcSEcCtD
Sorafenib—Syncope—Methylprednisolone—ankylosing spondylitis	0.000124	0.00186	CcSEcCtD
Sorafenib—Connective tissue disorder—Prednisone—ankylosing spondylitis	0.000123	0.00185	CcSEcCtD
Sorafenib—Anaphylactic shock—Prednisolone—ankylosing spondylitis	0.000123	0.00184	CcSEcCtD
Sorafenib—Neutropenia—Methotrexate—ankylosing spondylitis	0.000123	0.00184	CcSEcCtD
Sorafenib—Loss of consciousness—Triamcinolone—ankylosing spondylitis	0.000122	0.00182	CcSEcCtD
Sorafenib—Loss of consciousness—Methylprednisolone—ankylosing spondylitis	0.000121	0.00182	CcSEcCtD
Sorafenib—Shock—Prednisolone—ankylosing spondylitis	0.000121	0.00181	CcSEcCtD
Sorafenib—Erectile dysfunction—Methotrexate—ankylosing spondylitis	0.000121	0.00181	CcSEcCtD
Sorafenib—Cough—Triamcinolone—ankylosing spondylitis	0.000121	0.00181	CcSEcCtD
Sorafenib—Hypertension—Triamcinolone—ankylosing spondylitis	0.000119	0.00179	CcSEcCtD
Sorafenib—Hypertension—Methylprednisolone—ankylosing spondylitis	0.000119	0.00179	CcSEcCtD
Sorafenib—Myalgia—Triamcinolone—ankylosing spondylitis	0.000118	0.00177	CcSEcCtD
Sorafenib—Pneumonia—Methotrexate—ankylosing spondylitis	0.000118	0.00176	CcSEcCtD
Sorafenib—Arthralgia—Methylprednisolone—ankylosing spondylitis	0.000117	0.00176	CcSEcCtD
Sorafenib—Myalgia—Methylprednisolone—ankylosing spondylitis	0.000117	0.00176	CcSEcCtD
Sorafenib—Infestation—Methotrexate—ankylosing spondylitis	0.000117	0.00175	CcSEcCtD
Sorafenib—Infestation NOS—Methotrexate—ankylosing spondylitis	0.000117	0.00175	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—ankylosing spondylitis	0.000117	0.00175	CcSEcCtD
Sorafenib—Flushing—Prednisone—ankylosing spondylitis	0.000116	0.00175	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Methotrexate—ankylosing spondylitis	0.000116	0.00174	CcSEcCtD
Sorafenib—Dry mouth—Triamcinolone—ankylosing spondylitis	0.000115	0.00173	CcSEcCtD
Sorafenib—Renal failure—Methotrexate—ankylosing spondylitis	0.000115	0.00172	CcSEcCtD
Sorafenib—Angioedema—Dexamethasone—ankylosing spondylitis	0.000115	0.00172	CcSEcCtD
Sorafenib—Angioedema—Betamethasone—ankylosing spondylitis	0.000115	0.00172	CcSEcCtD
Sorafenib—Stomatitis—Methotrexate—ankylosing spondylitis	0.000114	0.00171	CcSEcCtD
Sorafenib—Angiopathy—Prednisone—ankylosing spondylitis	0.000114	0.00171	CcSEcCtD
Sorafenib—Immune system disorder—Prednisone—ankylosing spondylitis	0.000113	0.0017	CcSEcCtD
Sorafenib—Anaphylactic shock—Triamcinolone—ankylosing spondylitis	0.000113	0.00169	CcSEcCtD
Sorafenib—Anaphylactic shock—Methylprednisolone—ankylosing spondylitis	0.000113	0.00169	CcSEcCtD
Sorafenib—Syncope—Dexamethasone—ankylosing spondylitis	0.000113	0.00169	CcSEcCtD
Sorafenib—Syncope—Betamethasone—ankylosing spondylitis	0.000113	0.00169	CcSEcCtD
Sorafenib—Arrhythmia—Prednisone—ankylosing spondylitis	0.000112	0.00168	CcSEcCtD
Sorafenib—Infection—Triamcinolone—ankylosing spondylitis	0.000112	0.00168	CcSEcCtD
Sorafenib—Infection—Methylprednisolone—ankylosing spondylitis	0.000112	0.00168	CcSEcCtD
Sorafenib—Shock—Triamcinolone—ankylosing spondylitis	0.000111	0.00167	CcSEcCtD
Sorafenib—Alopecia—Prednisone—ankylosing spondylitis	0.000111	0.00167	CcSEcCtD
Sorafenib—Shock—Methylprednisolone—ankylosing spondylitis	0.000111	0.00166	CcSEcCtD
Sorafenib—Hepatobiliary disease—Methotrexate—ankylosing spondylitis	0.000111	0.00166	CcSEcCtD
Sorafenib—Nervous system disorder—Methylprednisolone—ankylosing spondylitis	0.00011	0.00166	CcSEcCtD
Sorafenib—Loss of consciousness—Dexamethasone—ankylosing spondylitis	0.00011	0.00166	CcSEcCtD
Sorafenib—Loss of consciousness—Betamethasone—ankylosing spondylitis	0.00011	0.00166	CcSEcCtD
Sorafenib—Epistaxis—Methotrexate—ankylosing spondylitis	0.00011	0.00165	CcSEcCtD
Sorafenib—Mental disorder—Prednisone—ankylosing spondylitis	0.00011	0.00165	CcSEcCtD
Sorafenib—Skin disorder—Methylprednisolone—ankylosing spondylitis	0.000109	0.00164	CcSEcCtD
Sorafenib—Erythema—Prednisone—ankylosing spondylitis	0.000109	0.00164	CcSEcCtD
Sorafenib—Malnutrition—Prednisone—ankylosing spondylitis	0.000109	0.00164	CcSEcCtD
Sorafenib—Hypertension—Dexamethasone—ankylosing spondylitis	0.000108	0.00163	CcSEcCtD
Sorafenib—Hypertension—Betamethasone—ankylosing spondylitis	0.000108	0.00163	CcSEcCtD
Sorafenib—Myalgia—Dexamethasone—ankylosing spondylitis	0.000107	0.0016	CcSEcCtD
Sorafenib—Myalgia—Betamethasone—ankylosing spondylitis	0.000107	0.0016	CcSEcCtD
Sorafenib—Haemoglobin—Methotrexate—ankylosing spondylitis	0.000105	0.00158	CcSEcCtD
Sorafenib—Pain—Prednisolone—ankylosing spondylitis	0.000105	0.00158	CcSEcCtD
Sorafenib—Haemorrhage—Methotrexate—ankylosing spondylitis	0.000105	0.00157	CcSEcCtD
Sorafenib—Urinary tract disorder—Methotrexate—ankylosing spondylitis	0.000104	0.00156	CcSEcCtD
Sorafenib—Urethral disorder—Methotrexate—ankylosing spondylitis	0.000103	0.00154	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Triamcinolone—ankylosing spondylitis	0.000103	0.00154	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Methylprednisolone—ankylosing spondylitis	0.000103	0.00154	CcSEcCtD
Sorafenib—Anaphylactic shock—Dexamethasone—ankylosing spondylitis	0.000102	0.00154	CcSEcCtD
Sorafenib—Anaphylactic shock—Betamethasone—ankylosing spondylitis	0.000102	0.00154	CcSEcCtD
Sorafenib—Infection—Betamethasone—ankylosing spondylitis	0.000102	0.00153	CcSEcCtD
Sorafenib—Infection—Dexamethasone—ankylosing spondylitis	0.000102	0.00153	CcSEcCtD
Sorafenib—Anaemia—Prednisone—ankylosing spondylitis	0.000101	0.00152	CcSEcCtD
Sorafenib—Shock—Betamethasone—ankylosing spondylitis	0.000101	0.00151	CcSEcCtD
Sorafenib—Shock—Dexamethasone—ankylosing spondylitis	0.000101	0.00151	CcSEcCtD
Sorafenib—Dyspnoea—Triamcinolone—ankylosing spondylitis	0.000101	0.00151	CcSEcCtD
Sorafenib—Nervous system disorder—Betamethasone—ankylosing spondylitis	0.0001	0.00151	CcSEcCtD
Sorafenib—Nervous system disorder—Dexamethasone—ankylosing spondylitis	0.0001	0.00151	CcSEcCtD
Sorafenib—Thrombocytopenia—Betamethasone—ankylosing spondylitis	0.0001	0.00151	CcSEcCtD
Sorafenib—Thrombocytopenia—Dexamethasone—ankylosing spondylitis	0.0001	0.00151	CcSEcCtD
Sorafenib—Angioedema—Prednisone—ankylosing spondylitis	9.98e-05	0.0015	CcSEcCtD
Sorafenib—Dyspepsia—Triamcinolone—ankylosing spondylitis	9.93e-05	0.00149	CcSEcCtD
Sorafenib—Erythema multiforme—Methotrexate—ankylosing spondylitis	9.92e-05	0.00149	CcSEcCtD
Sorafenib—Dyspepsia—Methylprednisolone—ankylosing spondylitis	9.91e-05	0.00149	CcSEcCtD
Sorafenib—Syncope—Prednisone—ankylosing spondylitis	9.8e-05	0.00147	CcSEcCtD
Sorafenib—Tinnitus—Methotrexate—ankylosing spondylitis	9.78e-05	0.00147	CcSEcCtD
Sorafenib—Anorexia—Dexamethasone—ankylosing spondylitis	9.76e-05	0.00147	CcSEcCtD
Sorafenib—Anorexia—Betamethasone—ankylosing spondylitis	9.76e-05	0.00147	CcSEcCtD
Sorafenib—Urticaria—Prednisolone—ankylosing spondylitis	9.75e-05	0.00146	CcSEcCtD
Sorafenib—Cardiac disorder—Methotrexate—ankylosing spondylitis	9.73e-05	0.00146	CcSEcCtD
Sorafenib—Fatigue—Triamcinolone—ankylosing spondylitis	9.73e-05	0.00146	CcSEcCtD
Sorafenib—Fatigue—Methylprednisolone—ankylosing spondylitis	9.71e-05	0.00146	CcSEcCtD
Sorafenib—Pain—Triamcinolone—ankylosing spondylitis	9.65e-05	0.00145	CcSEcCtD
Sorafenib—Loss of consciousness—Prednisone—ankylosing spondylitis	9.6e-05	0.00144	CcSEcCtD
Sorafenib—Angiopathy—Methotrexate—ankylosing spondylitis	9.52e-05	0.00143	CcSEcCtD
Sorafenib—TAOK2—tendon—ankylosing spondylitis	9.51e-05	0.0642	CbGeAlD
Sorafenib—Immune system disorder—Methotrexate—ankylosing spondylitis	9.47e-05	0.00142	CcSEcCtD
Sorafenib—Mediastinal disorder—Methotrexate—ankylosing spondylitis	9.45e-05	0.00142	CcSEcCtD
Sorafenib—AURKC—tendon—ankylosing spondylitis	9.44e-05	0.0637	CbGeAlD
Sorafenib—Hypertension—Prednisone—ankylosing spondylitis	9.43e-05	0.00142	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Betamethasone—ankylosing spondylitis	9.33e-05	0.0014	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Dexamethasone—ankylosing spondylitis	9.33e-05	0.0014	CcSEcCtD
Sorafenib—Arthralgia—Prednisone—ankylosing spondylitis	9.3e-05	0.0014	CcSEcCtD
Sorafenib—Myalgia—Prednisone—ankylosing spondylitis	9.3e-05	0.0014	CcSEcCtD
Sorafenib—Alopecia—Methotrexate—ankylosing spondylitis	9.27e-05	0.00139	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	9.24e-05	0.00139	CcSEcCtD
Sorafenib—Gastrointestinal pain—Methylprednisolone—ankylosing spondylitis	9.21e-05	0.00138	CcSEcCtD
Sorafenib—Mental disorder—Methotrexate—ankylosing spondylitis	9.19e-05	0.00138	CcSEcCtD
Sorafenib—Malnutrition—Methotrexate—ankylosing spondylitis	9.13e-05	0.00137	CcSEcCtD
Sorafenib—Erythema—Methotrexate—ankylosing spondylitis	9.13e-05	0.00137	CcSEcCtD
Sorafenib—Hypersensitivity—Prednisolone—ankylosing spondylitis	9.04e-05	0.00136	CcSEcCtD
Sorafenib—Dyspepsia—Dexamethasone—ankylosing spondylitis	9.01e-05	0.00135	CcSEcCtD
Sorafenib—Dyspepsia—Betamethasone—ankylosing spondylitis	9.01e-05	0.00135	CcSEcCtD
Sorafenib—Urticaria—Triamcinolone—ankylosing spondylitis	8.96e-05	0.00135	CcSEcCtD
Sorafenib—Urticaria—Methylprednisolone—ankylosing spondylitis	8.94e-05	0.00134	CcSEcCtD
Sorafenib—Dysgeusia—Methotrexate—ankylosing spondylitis	8.94e-05	0.00134	CcSEcCtD
Sorafenib—Body temperature increased—Triamcinolone—ankylosing spondylitis	8.92e-05	0.00134	CcSEcCtD
Sorafenib—Anaphylactic shock—Prednisone—ankylosing spondylitis	8.92e-05	0.00134	CcSEcCtD
Sorafenib—Abdominal pain—Methylprednisolone—ankylosing spondylitis	8.9e-05	0.00134	CcSEcCtD
Sorafenib—Decreased appetite—Betamethasone—ankylosing spondylitis	8.9e-05	0.00134	CcSEcCtD
Sorafenib—Decreased appetite—Dexamethasone—ankylosing spondylitis	8.9e-05	0.00134	CcSEcCtD
Sorafenib—Infection—Prednisone—ankylosing spondylitis	8.86e-05	0.00133	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	8.84e-05	0.00133	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	8.84e-05	0.00133	CcSEcCtD
Sorafenib—Fatigue—Betamethasone—ankylosing spondylitis	8.83e-05	0.00133	CcSEcCtD
Sorafenib—Fatigue—Dexamethasone—ankylosing spondylitis	8.83e-05	0.00133	CcSEcCtD
Sorafenib—Shock—Prednisone—ankylosing spondylitis	8.77e-05	0.00132	CcSEcCtD
Sorafenib—Pain—Betamethasone—ankylosing spondylitis	8.76e-05	0.00131	CcSEcCtD
Sorafenib—Pain—Dexamethasone—ankylosing spondylitis	8.76e-05	0.00131	CcSEcCtD
Sorafenib—Nervous system disorder—Prednisone—ankylosing spondylitis	8.74e-05	0.00131	CcSEcCtD
Sorafenib—Skin disorder—Prednisone—ankylosing spondylitis	8.66e-05	0.0013	CcSEcCtD
Sorafenib—Anorexia—Prednisone—ankylosing spondylitis	8.5e-05	0.00128	CcSEcCtD
Sorafenib—Anaemia—Methotrexate—ankylosing spondylitis	8.44e-05	0.00127	CcSEcCtD
Sorafenib—Gastrointestinal pain—Dexamethasone—ankylosing spondylitis	8.37e-05	0.00126	CcSEcCtD
Sorafenib—Gastrointestinal pain—Betamethasone—ankylosing spondylitis	8.37e-05	0.00126	CcSEcCtD
Sorafenib—Hypersensitivity—Triamcinolone—ankylosing spondylitis	8.31e-05	0.00125	CcSEcCtD
Sorafenib—Hypersensitivity—Methylprednisolone—ankylosing spondylitis	8.3e-05	0.00125	CcSEcCtD
Sorafenib—ZAK—tendon—ankylosing spondylitis	8.29e-05	0.0559	CbGeAlD
Sorafenib—Leukopenia—Methotrexate—ankylosing spondylitis	8.17e-05	0.00123	CcSEcCtD
Sorafenib—Urticaria—Dexamethasone—ankylosing spondylitis	8.13e-05	0.00122	CcSEcCtD
Sorafenib—Urticaria—Betamethasone—ankylosing spondylitis	8.13e-05	0.00122	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Prednisone—ankylosing spondylitis	8.12e-05	0.00122	CcSEcCtD
Sorafenib—Dizziness—Prednisolone—ankylosing spondylitis	8.11e-05	0.00122	CcSEcCtD
Sorafenib—HIPK3—tendon—ankylosing spondylitis	8.11e-05	0.0547	CbGeAlD
Sorafenib—Asthenia—Triamcinolone—ankylosing spondylitis	8.1e-05	0.00122	CcSEcCtD
Sorafenib—Abdominal pain—Betamethasone—ankylosing spondylitis	8.09e-05	0.00122	CcSEcCtD
Sorafenib—Abdominal pain—Dexamethasone—ankylosing spondylitis	8.09e-05	0.00122	CcSEcCtD
Sorafenib—Body temperature increased—Betamethasone—ankylosing spondylitis	8.09e-05	0.00122	CcSEcCtD
Sorafenib—Body temperature increased—Dexamethasone—ankylosing spondylitis	8.09e-05	0.00122	CcSEcCtD
Sorafenib—Asthenia—Methylprednisolone—ankylosing spondylitis	8.08e-05	0.00121	CcSEcCtD
Sorafenib—Pruritus—Triamcinolone—ankylosing spondylitis	7.98e-05	0.0012	CcSEcCtD
Sorafenib—Cough—Methotrexate—ankylosing spondylitis	7.97e-05	0.0012	CcSEcCtD
Sorafenib—Pruritus—Methylprednisolone—ankylosing spondylitis	7.97e-05	0.0012	CcSEcCtD
Sorafenib—Dyspepsia—Prednisone—ankylosing spondylitis	7.85e-05	0.00118	CcSEcCtD
Sorafenib—Myalgia—Methotrexate—ankylosing spondylitis	7.77e-05	0.00117	CcSEcCtD
Sorafenib—Arthralgia—Methotrexate—ankylosing spondylitis	7.77e-05	0.00117	CcSEcCtD
Sorafenib—Decreased appetite—Prednisone—ankylosing spondylitis	7.75e-05	0.00116	CcSEcCtD
Sorafenib—Rash—Prednisolone—ankylosing spondylitis	7.74e-05	0.00116	CcSEcCtD
Sorafenib—Dermatitis—Prednisolone—ankylosing spondylitis	7.73e-05	0.00116	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	7.72e-05	0.00116	CcSEcCtD
Sorafenib—Diarrhoea—Methylprednisolone—ankylosing spondylitis	7.7e-05	0.00116	CcSEcCtD
Sorafenib—Fatigue—Prednisone—ankylosing spondylitis	7.69e-05	0.00115	CcSEcCtD
Sorafenib—Headache—Prednisolone—ankylosing spondylitis	7.69e-05	0.00115	CcSEcCtD
Sorafenib—Constipation—Prednisone—ankylosing spondylitis	7.63e-05	0.00114	CcSEcCtD
Sorafenib—Dizziness—Triamcinolone—ankylosing spondylitis	7.46e-05	0.00112	CcSEcCtD
Sorafenib—Anaphylactic shock—Methotrexate—ankylosing spondylitis	7.45e-05	0.00112	CcSEcCtD
Sorafenib—Dizziness—Methylprednisolone—ankylosing spondylitis	7.45e-05	0.00112	CcSEcCtD
Sorafenib—Infection—Methotrexate—ankylosing spondylitis	7.4e-05	0.00111	CcSEcCtD
Sorafenib—Asthenia—Dexamethasone—ankylosing spondylitis	7.35e-05	0.0011	CcSEcCtD
Sorafenib—Asthenia—Betamethasone—ankylosing spondylitis	7.35e-05	0.0011	CcSEcCtD
Sorafenib—Nervous system disorder—Methotrexate—ankylosing spondylitis	7.31e-05	0.0011	CcSEcCtD
Sorafenib—Thrombocytopenia—Methotrexate—ankylosing spondylitis	7.3e-05	0.0011	CcSEcCtD
Sorafenib—Gastrointestinal pain—Prednisone—ankylosing spondylitis	7.29e-05	0.00109	CcSEcCtD
Sorafenib—Nausea—Prednisolone—ankylosing spondylitis	7.29e-05	0.00109	CcSEcCtD
Sorafenib—BRAF—tendon—ankylosing spondylitis	7.27e-05	0.049	CbGeAlD
Sorafenib—Pruritus—Dexamethasone—ankylosing spondylitis	7.24e-05	0.00109	CcSEcCtD
Sorafenib—Pruritus—Betamethasone—ankylosing spondylitis	7.24e-05	0.00109	CcSEcCtD
Sorafenib—Skin disorder—Methotrexate—ankylosing spondylitis	7.24e-05	0.00109	CcSEcCtD
Sorafenib—Vomiting—Triamcinolone—ankylosing spondylitis	7.17e-05	0.00108	CcSEcCtD
Sorafenib—Vomiting—Methylprednisolone—ankylosing spondylitis	7.16e-05	0.00107	CcSEcCtD
Sorafenib—Rash—Triamcinolone—ankylosing spondylitis	7.11e-05	0.00107	CcSEcCtD
Sorafenib—Dermatitis—Triamcinolone—ankylosing spondylitis	7.11e-05	0.00107	CcSEcCtD
Sorafenib—Anorexia—Methotrexate—ankylosing spondylitis	7.1e-05	0.00107	CcSEcCtD
Sorafenib—Rash—Methylprednisolone—ankylosing spondylitis	7.1e-05	0.00107	CcSEcCtD
Sorafenib—Dermatitis—Methylprednisolone—ankylosing spondylitis	7.09e-05	0.00106	CcSEcCtD
Sorafenib—Urticaria—Prednisone—ankylosing spondylitis	7.08e-05	0.00106	CcSEcCtD
Sorafenib—Headache—Triamcinolone—ankylosing spondylitis	7.07e-05	0.00106	CcSEcCtD
Sorafenib—Headache—Methylprednisolone—ankylosing spondylitis	7.05e-05	0.00106	CcSEcCtD
Sorafenib—Body temperature increased—Prednisone—ankylosing spondylitis	7.05e-05	0.00106	CcSEcCtD
Sorafenib—Abdominal pain—Prednisone—ankylosing spondylitis	7.05e-05	0.00106	CcSEcCtD
Sorafenib—Diarrhoea—Betamethasone—ankylosing spondylitis	7.01e-05	0.00105	CcSEcCtD
Sorafenib—Diarrhoea—Dexamethasone—ankylosing spondylitis	7.01e-05	0.00105	CcSEcCtD
Sorafenib—EPHX2—tendon—ankylosing spondylitis	6.94e-05	0.0468	CbGeAlD
Sorafenib—Musculoskeletal discomfort—Methotrexate—ankylosing spondylitis	6.79e-05	0.00102	CcSEcCtD
Sorafenib—Dizziness—Betamethasone—ankylosing spondylitis	6.77e-05	0.00102	CcSEcCtD
Sorafenib—Dizziness—Dexamethasone—ankylosing spondylitis	6.77e-05	0.00102	CcSEcCtD
Sorafenib—Nausea—Triamcinolone—ankylosing spondylitis	6.7e-05	0.00101	CcSEcCtD
Sorafenib—Nausea—Methylprednisolone—ankylosing spondylitis	6.69e-05	0.001	CcSEcCtD
Sorafenib—Dyspnoea—Methotrexate—ankylosing spondylitis	6.64e-05	0.000997	CcSEcCtD
Sorafenib—Hypersensitivity—Prednisone—ankylosing spondylitis	6.57e-05	0.000986	CcSEcCtD
Sorafenib—Dyspepsia—Methotrexate—ankylosing spondylitis	6.56e-05	0.000985	CcSEcCtD
Sorafenib—Vomiting—Dexamethasone—ankylosing spondylitis	6.51e-05	0.000977	CcSEcCtD
Sorafenib—Vomiting—Betamethasone—ankylosing spondylitis	6.51e-05	0.000977	CcSEcCtD
Sorafenib—Decreased appetite—Methotrexate—ankylosing spondylitis	6.48e-05	0.000973	CcSEcCtD
Sorafenib—Rash—Dexamethasone—ankylosing spondylitis	6.46e-05	0.000969	CcSEcCtD
Sorafenib—Rash—Betamethasone—ankylosing spondylitis	6.46e-05	0.000969	CcSEcCtD
Sorafenib—Dermatitis—Dexamethasone—ankylosing spondylitis	6.45e-05	0.000968	CcSEcCtD
Sorafenib—Dermatitis—Betamethasone—ankylosing spondylitis	6.45e-05	0.000968	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	6.43e-05	0.000966	CcSEcCtD
Sorafenib—Fatigue—Methotrexate—ankylosing spondylitis	6.42e-05	0.000965	CcSEcCtD
Sorafenib—Headache—Betamethasone—ankylosing spondylitis	6.41e-05	0.000963	CcSEcCtD
Sorafenib—Headache—Dexamethasone—ankylosing spondylitis	6.41e-05	0.000963	CcSEcCtD
Sorafenib—Asthenia—Prednisone—ankylosing spondylitis	6.4e-05	0.00096	CcSEcCtD
Sorafenib—Pain—Methotrexate—ankylosing spondylitis	6.37e-05	0.000957	CcSEcCtD
Sorafenib—Pruritus—Prednisone—ankylosing spondylitis	6.31e-05	0.000947	CcSEcCtD
Sorafenib—FGFR1—tendon—ankylosing spondylitis	6.18e-05	0.0417	CbGeAlD
Sorafenib—Diarrhoea—Prednisone—ankylosing spondylitis	6.1e-05	0.000916	CcSEcCtD
Sorafenib—Gastrointestinal pain—Methotrexate—ankylosing spondylitis	6.09e-05	0.000915	CcSEcCtD
Sorafenib—Nausea—Betamethasone—ankylosing spondylitis	6.08e-05	0.000913	CcSEcCtD
Sorafenib—Nausea—Dexamethasone—ankylosing spondylitis	6.08e-05	0.000913	CcSEcCtD
Sorafenib—Urticaria—Methotrexate—ankylosing spondylitis	5.92e-05	0.000889	CcSEcCtD
Sorafenib—Dizziness—Prednisone—ankylosing spondylitis	5.9e-05	0.000885	CcSEcCtD
Sorafenib—Abdominal pain—Methotrexate—ankylosing spondylitis	5.89e-05	0.000884	CcSEcCtD
Sorafenib—Body temperature increased—Methotrexate—ankylosing spondylitis	5.89e-05	0.000884	CcSEcCtD
Sorafenib—MAP3K7—tendon—ankylosing spondylitis	5.85e-05	0.0395	CbGeAlD
Sorafenib—PDGFRA—Allograft Rejection—TNF—ankylosing spondylitis	5.69e-05	0.00107	CbGpPWpGaD
Sorafenib—Vomiting—Prednisone—ankylosing spondylitis	5.67e-05	0.000851	CcSEcCtD
Sorafenib—MKNK2—tendon—ankylosing spondylitis	5.67e-05	0.0382	CbGeAlD
Sorafenib—ABCB1—Allograft Rejection—IL10—ankylosing spondylitis	5.66e-05	0.00107	CbGpPWpGaD
Sorafenib—ABCB1—Allograft Rejection—CD40LG—ankylosing spondylitis	5.66e-05	0.00107	CbGpPWpGaD
Sorafenib—Rash—Prednisone—ankylosing spondylitis	5.62e-05	0.000844	CcSEcCtD
Sorafenib—Dermatitis—Prednisone—ankylosing spondylitis	5.62e-05	0.000843	CcSEcCtD
Sorafenib—Headache—Prednisone—ankylosing spondylitis	5.59e-05	0.000839	CcSEcCtD
Sorafenib—KIT—Immune System—IL1R2—ankylosing spondylitis	5.53e-05	0.00104	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—IL1R2—ankylosing spondylitis	5.53e-05	0.00104	CbGpPWpGaD
Sorafenib—RET—tendon—ankylosing spondylitis	5.53e-05	0.0373	CbGeAlD
Sorafenib—Hypersensitivity—Methotrexate—ankylosing spondylitis	5.49e-05	0.000824	CcSEcCtD
Sorafenib—MAP3K7—Cytokine Signaling in Immune system—HLA-B—ankylosing spondylitis	5.45e-05	0.00103	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—ANTXR2—ankylosing spondylitis	5.45e-05	0.00103	CbGpPWpGaD
Sorafenib—MAPK11—Toll-like Receptor Signaling Pathway—TNF—ankylosing spondylitis	5.43e-05	0.00102	CbGpPWpGaD
Sorafenib—ABCB1—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	5.4e-05	0.00102	CbGpPWpGaD
Sorafenib—ABCB1—Allograft Rejection—HLA-B—ankylosing spondylitis	5.38e-05	0.00101	CbGpPWpGaD
Sorafenib—Asthenia—Methotrexate—ankylosing spondylitis	5.35e-05	0.000803	CcSEcCtD
Sorafenib—MAPK11—Immune System—CARD9—ankylosing spondylitis	5.32e-05	0.001	CbGpPWpGaD
Sorafenib—MAP3K7—TNF alpha Signaling Pathway—TNF—ankylosing spondylitis	5.32e-05	0.001	CbGpPWpGaD
Sorafenib—Nausea—Prednisone—ankylosing spondylitis	5.3e-05	0.000795	CcSEcCtD
Sorafenib—Pruritus—Methotrexate—ankylosing spondylitis	5.27e-05	0.000792	CcSEcCtD
Sorafenib—RAF1—Downstream signaling in naïve CD8+ T cells—TNF—ankylosing spondylitis	5.27e-05	0.000994	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—IL1R2—ankylosing spondylitis	5.25e-05	0.00099	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—ERAP1—ankylosing spondylitis	5.25e-05	0.000989	CbGpPWpGaD
Sorafenib—KIT—Immune System—ERAP1—ankylosing spondylitis	5.25e-05	0.000989	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—IL1R2—ankylosing spondylitis	5.24e-05	0.000988	CbGpPWpGaD
Sorafenib—KIT—Innate Immune System—HLA-C—ankylosing spondylitis	5.17e-05	0.000975	CbGpPWpGaD
Sorafenib—MAP3K7—Innate Immune System—HLA-C—ankylosing spondylitis	5.17e-05	0.000975	CbGpPWpGaD
Sorafenib—HTR2C—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	5.14e-05	0.000969	CbGpPWpGaD
Sorafenib—RALBP1—tendon—ankylosing spondylitis	5.12e-05	0.0345	CbGeAlD
Sorafenib—Diarrhoea—Methotrexate—ankylosing spondylitis	5.1e-05	0.000765	CcSEcCtD
Sorafenib—MAP3K7—Cytokine Signaling in Immune system—HLA-A—ankylosing spondylitis	5.05e-05	0.000953	CbGpPWpGaD
Sorafenib—ABCB1—Allograft Rejection—HLA-A—ankylosing spondylitis	4.99e-05	0.00094	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—ERAP1—ankylosing spondylitis	4.98e-05	0.000939	CbGpPWpGaD
Sorafenib—MAP3K7—Adaptive Immune System—HLA-C—ankylosing spondylitis	4.97e-05	0.000937	CbGpPWpGaD
Sorafenib—KIT—Adaptive Immune System—HLA-C—ankylosing spondylitis	4.97e-05	0.000937	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—ERAP1—ankylosing spondylitis	4.97e-05	0.000936	CbGpPWpGaD
Sorafenib—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—ankylosing spondylitis	4.94e-05	0.000932	CbGpPWpGaD
Sorafenib—Dizziness—Methotrexate—ankylosing spondylitis	4.93e-05	0.00074	CcSEcCtD
Sorafenib—FGFR1—Innate Immune System—HLA-C—ankylosing spondylitis	4.91e-05	0.000926	CbGpPWpGaD
Sorafenib—PDGFRA—Innate Immune System—HLA-C—ankylosing spondylitis	4.9e-05	0.000923	CbGpPWpGaD
Sorafenib—MAP3K7—Toll-like Receptor Signaling Pathway—TNF—ankylosing spondylitis	4.9e-05	0.000923	CbGpPWpGaD
Sorafenib—FLT1—tendon—ankylosing spondylitis	4.87e-05	0.0328	CbGeAlD
Sorafenib—RAF1—Disease—ANTXR2—ankylosing spondylitis	4.86e-05	0.000916	CbGpPWpGaD
Sorafenib—HTR2B—GPCR ligand binding—PTGER4—ankylosing spondylitis	4.85e-05	0.000915	CbGpPWpGaD
Sorafenib—RAF1—tendon—ankylosing spondylitis	4.84e-05	0.0327	CbGeAlD
Sorafenib—EPHB6—tendon—ankylosing spondylitis	4.81e-05	0.0325	CbGeAlD
Sorafenib—KIT—Immune System—CARD9—ankylosing spondylitis	4.8e-05	0.000905	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—CARD9—ankylosing spondylitis	4.8e-05	0.000905	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—PTGER4—ankylosing spondylitis	4.78e-05	0.000901	CbGpPWpGaD
Sorafenib—Vomiting—Methotrexate—ankylosing spondylitis	4.74e-05	0.000711	CcSEcCtD
Sorafenib—PDGFRB—Immune System—IL1R2—ankylosing spondylitis	4.72e-05	0.00089	CbGpPWpGaD
Sorafenib—FGFR1—Adaptive Immune System—HLA-C—ankylosing spondylitis	4.71e-05	0.000889	CbGpPWpGaD
Sorafenib—PDGFRA—Adaptive Immune System—HLA-C—ankylosing spondylitis	4.7e-05	0.000887	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—PTGER4—ankylosing spondylitis	4.7e-05	0.000886	CbGpPWpGaD
Sorafenib—Rash—Methotrexate—ankylosing spondylitis	4.7e-05	0.000705	CcSEcCtD
Sorafenib—Dermatitis—Methotrexate—ankylosing spondylitis	4.69e-05	0.000705	CcSEcCtD
Sorafenib—Headache—Methotrexate—ankylosing spondylitis	4.67e-05	0.000701	CcSEcCtD
Sorafenib—STK10—tendon—ankylosing spondylitis	4.61e-05	0.0311	CbGeAlD
Sorafenib—PDGFRA—tendon—ankylosing spondylitis	4.56e-05	0.0308	CbGeAlD
Sorafenib—FGFR1—Immune System—CARD9—ankylosing spondylitis	4.55e-05	0.000859	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—CARD9—ankylosing spondylitis	4.54e-05	0.000856	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—ERAP1—ankylosing spondylitis	4.47e-05	0.000844	CbGpPWpGaD
Sorafenib—Nausea—Methotrexate—ankylosing spondylitis	4.43e-05	0.000665	CcSEcCtD
Sorafenib—PDGFRB—Innate Immune System—HLA-C—ankylosing spondylitis	4.41e-05	0.000832	CbGpPWpGaD
Sorafenib—RAF1—Cytokine Signaling in Immune system—IL1A—ankylosing spondylitis	4.38e-05	0.000827	CbGpPWpGaD
Sorafenib—MAP2K5—MAPK Signaling Pathway—TNF—ankylosing spondylitis	4.35e-05	0.00082	CbGpPWpGaD
Sorafenib—RAF1—MicroRNAs in cardiomyocyte hypertrophy—TNF—ankylosing spondylitis	4.35e-05	0.00082	CbGpPWpGaD
Sorafenib—MAPK11—Regulation of toll-like receptor signaling pathway—TNF—ankylosing spondylitis	4.24e-05	0.000799	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—HLA-C—ankylosing spondylitis	4.24e-05	0.000799	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL1R2—ankylosing spondylitis	4.21e-05	0.000793	CbGpPWpGaD
Sorafenib—RAF1—Cytokine Signaling in Immune system—HLA-B—ankylosing spondylitis	4.15e-05	0.000782	CbGpPWpGaD
Sorafenib—BRAF—Disease—B3GNT2—ankylosing spondylitis	4.14e-05	0.00078	CbGpPWpGaD
Sorafenib—KDR—tendon—ankylosing spondylitis	4.12e-05	0.0278	CbGeAlD
Sorafenib—MAP2K5—tendon—ankylosing spondylitis	4.12e-05	0.0278	CbGeAlD
Sorafenib—PDGFRB—Immune System—CARD9—ankylosing spondylitis	4.09e-05	0.000771	CbGpPWpGaD
Sorafenib—RAF1—TNF alpha Signaling Pathway—TNF—ankylosing spondylitis	4.04e-05	0.000762	CbGpPWpGaD
Sorafenib—CSF1R—tendon—ankylosing spondylitis	4.02e-05	0.0271	CbGeAlD
Sorafenib—RAF1—Immune System—ERAP1—ankylosing spondylitis	3.99e-05	0.000752	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—HLA-C—ankylosing spondylitis	3.93e-05	0.000741	CbGpPWpGaD
Sorafenib—HTR2C—GPCR ligand binding—PTGER4—ankylosing spondylitis	3.92e-05	0.000738	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—PTGER4—ankylosing spondylitis	3.89e-05	0.000734	CbGpPWpGaD
Sorafenib—RAF1—Cytokine Signaling in Immune system—HLA-A—ankylosing spondylitis	3.84e-05	0.000724	CbGpPWpGaD
Sorafenib—MAP3K7—Regulation of toll-like receptor signaling pathway—TNF—ankylosing spondylitis	3.82e-05	0.000721	CbGpPWpGaD
Sorafenib—MAP3K7—Adaptive Immune System—CD79A—ankylosing spondylitis	3.79e-05	0.000714	CbGpPWpGaD
Sorafenib—KIT—Adaptive Immune System—CD79A—ankylosing spondylitis	3.79e-05	0.000714	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—HLA-C—ankylosing spondylitis	3.78e-05	0.000712	CbGpPWpGaD
Sorafenib—KIT—Disease—B3GNT2—ankylosing spondylitis	3.77e-05	0.00071	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CARD9—ankylosing spondylitis	3.65e-05	0.000688	CbGpPWpGaD
Sorafenib—BRAF—MAPK Signaling Pathway—TNF—ankylosing spondylitis	3.61e-05	0.00068	CbGpPWpGaD
Sorafenib—FGFR1—Adaptive Immune System—CD79A—ankylosing spondylitis	3.6e-05	0.000678	CbGpPWpGaD
Sorafenib—PDGFRA—Adaptive Immune System—CD79A—ankylosing spondylitis	3.59e-05	0.000676	CbGpPWpGaD
Sorafenib—FGFR1—Disease—B3GNT2—ankylosing spondylitis	3.57e-05	0.000674	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—B3GNT2—ankylosing spondylitis	3.57e-05	0.000672	CbGpPWpGaD
Sorafenib—PDGFRB—tendon—ankylosing spondylitis	3.56e-05	0.024	CbGeAlD
Sorafenib—FLT1—Signaling Pathways—PTGER4—ankylosing spondylitis	3.51e-05	0.000661	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—MMP3—ankylosing spondylitis	3.4e-05	0.000641	CbGpPWpGaD
Sorafenib—MAPK11—Innate Immune System—HLA-B—ankylosing spondylitis	3.39e-05	0.00064	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—MMP3—ankylosing spondylitis	3.35e-05	0.000631	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—HLA-C—ankylosing spondylitis	3.34e-05	0.00063	CbGpPWpGaD
Sorafenib—MAP3K7—MAPK Signaling Pathway—TNF—ankylosing spondylitis	3.28e-05	0.000619	CbGpPWpGaD
Sorafenib—MKNK1—Disease—HLA-A—ankylosing spondylitis	3.28e-05	0.000619	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—CD79A—ankylosing spondylitis	3.23e-05	0.000609	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—B3GNT2—ankylosing spondylitis	3.21e-05	0.000606	CbGpPWpGaD
Sorafenib—FGFR1—MAPK Signaling Pathway—TNF—ankylosing spondylitis	3.12e-05	0.000588	CbGpPWpGaD
Sorafenib—MAP3K7—Adaptive Immune System—CD40LG—ankylosing spondylitis	3.09e-05	0.000582	CbGpPWpGaD
Sorafenib—KIT—Adaptive Immune System—CD40LG—ankylosing spondylitis	3.09e-05	0.000582	CbGpPWpGaD
Sorafenib—KIT—Innate Immune System—HLA-B—ankylosing spondylitis	3.06e-05	0.000577	CbGpPWpGaD
Sorafenib—MAP3K7—Innate Immune System—HLA-B—ankylosing spondylitis	3.06e-05	0.000577	CbGpPWpGaD
Sorafenib—KIT—Immune System—HLA-C—ankylosing spondylitis	3.01e-05	0.000568	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—HLA-C—ankylosing spondylitis	3.01e-05	0.000568	CbGpPWpGaD
Sorafenib—MAPK11—Innate Immune System—CRP—ankylosing spondylitis	3e-05	0.000565	CbGpPWpGaD
Sorafenib—MAP3K7—Adaptive Immune System—HLA-B—ankylosing spondylitis	2.94e-05	0.000554	CbGpPWpGaD
Sorafenib—KIT—Adaptive Immune System—HLA-B—ankylosing spondylitis	2.94e-05	0.000554	CbGpPWpGaD
Sorafenib—FGFR1—Adaptive Immune System—CD40LG—ankylosing spondylitis	2.93e-05	0.000553	CbGpPWpGaD
Sorafenib—EPHB6—Developmental Biology—TNF—ankylosing spondylitis	2.93e-05	0.000552	CbGpPWpGaD
Sorafenib—PDGFRA—Adaptive Immune System—CD40LG—ankylosing spondylitis	2.92e-05	0.000551	CbGpPWpGaD
Sorafenib—FGFR1—Innate Immune System—HLA-B—ankylosing spondylitis	2.9e-05	0.000547	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—IL1RN—ankylosing spondylitis	2.9e-05	0.000547	CbGpPWpGaD
Sorafenib—PDGFRA—Innate Immune System—HLA-B—ankylosing spondylitis	2.9e-05	0.000546	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—CD79A—ankylosing spondylitis	2.88e-05	0.000543	CbGpPWpGaD
Sorafenib—MAPK11—Innate Immune System—TLR4—ankylosing spondylitis	2.87e-05	0.000542	CbGpPWpGaD
Sorafenib—RAF1—Disease—B3GNT2—ankylosing spondylitis	2.86e-05	0.00054	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—HLA-C—ankylosing spondylitis	2.86e-05	0.000539	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—HLA-C—ankylosing spondylitis	2.85e-05	0.000538	CbGpPWpGaD
Sorafenib—ABCC4—tendon—ankylosing spondylitis	2.84e-05	0.0191	CbGeAlD
Sorafenib—HTR2B—tendon—ankylosing spondylitis	2.82e-05	0.019	CbGeAlD
Sorafenib—FGFR1—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	2.81e-05	0.00053	CbGpPWpGaD
Sorafenib—PDGFRA—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	2.81e-05	0.000529	CbGpPWpGaD
Sorafenib—PDGFRB—MAPK Signaling Pathway—TNF—ankylosing spondylitis	2.8e-05	0.000528	CbGpPWpGaD
Sorafenib—FGFR1—Adaptive Immune System—HLA-B—ankylosing spondylitis	2.79e-05	0.000526	CbGpPWpGaD
Sorafenib—PDGFRA—Adaptive Immune System—HLA-B—ankylosing spondylitis	2.78e-05	0.000524	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—MMP3—ankylosing spondylitis	2.77e-05	0.000523	CbGpPWpGaD
Sorafenib—EPHA6—Developmental Biology—TNF—ankylosing spondylitis	2.75e-05	0.000519	CbGpPWpGaD
Sorafenib—ABCC2—tendon—ankylosing spondylitis	2.75e-05	0.0185	CbGeAlD
Sorafenib—HTR2B—GPCR downstream signaling—PTGER4—ankylosing spondylitis	2.74e-05	0.000517	CbGpPWpGaD
Sorafenib—KIT—Adaptive Immune System—HLA-A—ankylosing spondylitis	2.72e-05	0.000513	CbGpPWpGaD
Sorafenib—MAP3K7—Adaptive Immune System—HLA-A—ankylosing spondylitis	2.72e-05	0.000513	CbGpPWpGaD
Sorafenib—KIT—Innate Immune System—CRP—ankylosing spondylitis	2.7e-05	0.00051	CbGpPWpGaD
Sorafenib—MAP3K7—Innate Immune System—CRP—ankylosing spondylitis	2.7e-05	0.00051	CbGpPWpGaD
Sorafenib—CYP1A2—Aryl Hydrocarbon Receptor—TNF—ankylosing spondylitis	2.65e-05	0.0005	CbGpPWpGaD
Sorafenib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—ankylosing spondylitis	2.65e-05	0.0005	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—CD40LG—ankylosing spondylitis	2.63e-05	0.000497	CbGpPWpGaD
Sorafenib—KIT—Immune System—IL1RN—ankylosing spondylitis	2.62e-05	0.000493	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—IL1RN—ankylosing spondylitis	2.62e-05	0.000493	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—HLA-B—ankylosing spondylitis	2.61e-05	0.000492	CbGpPWpGaD
Sorafenib—KIT—Innate Immune System—TLR4—ankylosing spondylitis	2.59e-05	0.000489	CbGpPWpGaD
Sorafenib—MAP3K7—Innate Immune System—TLR4—ankylosing spondylitis	2.59e-05	0.000489	CbGpPWpGaD
Sorafenib—FGFR1—Adaptive Immune System—HLA-A—ankylosing spondylitis	2.58e-05	0.000487	CbGpPWpGaD
Sorafenib—PDGFRA—Adaptive Immune System—HLA-A—ankylosing spondylitis	2.58e-05	0.000486	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—HLA-C—ankylosing spondylitis	2.57e-05	0.000484	CbGpPWpGaD
Sorafenib—FGFR1—Innate Immune System—CRP—ankylosing spondylitis	2.57e-05	0.000484	CbGpPWpGaD
Sorafenib—PDGFRA—Innate Immune System—CRP—ankylosing spondylitis	2.56e-05	0.000483	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—CD79A—ankylosing spondylitis	2.55e-05	0.00048	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—HLA-B—ankylosing spondylitis	2.5e-05	0.000472	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—MMP3—ankylosing spondylitis	2.5e-05	0.000471	CbGpPWpGaD
Sorafenib—RAF1—MAPK Signaling Pathway—TNF—ankylosing spondylitis	2.5e-05	0.000471	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—PTGER4—ankylosing spondylitis	2.49e-05	0.00047	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—IL1RN—ankylosing spondylitis	2.48e-05	0.000468	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—IL1RN—ankylosing spondylitis	2.48e-05	0.000467	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—B3GNT2—ankylosing spondylitis	2.46e-05	0.000465	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—B3GNT2—ankylosing spondylitis	2.46e-05	0.000465	CbGpPWpGaD
Sorafenib—FGFR1—Innate Immune System—TLR4—ankylosing spondylitis	2.46e-05	0.000464	CbGpPWpGaD
Sorafenib—PDGFRA—Innate Immune System—TLR4—ankylosing spondylitis	2.45e-05	0.000463	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—PTGER4—ankylosing spondylitis	2.39e-05	0.000451	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—CD40LG—ankylosing spondylitis	2.35e-05	0.000443	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—PTGER4—ankylosing spondylitis	2.33e-05	0.00044	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—PTGER4—ankylosing spondylitis	2.33e-05	0.000439	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—HLA-B—ankylosing spondylitis	2.33e-05	0.000438	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—HLA-A—ankylosing spondylitis	2.32e-05	0.000438	CbGpPWpGaD
Sorafenib—CDK7—Disease—HLA-A—ankylosing spondylitis	2.31e-05	0.000436	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—CRP—ankylosing spondylitis	2.31e-05	0.000435	CbGpPWpGaD
Sorafenib—KIT—Immune System—CD79A—ankylosing spondylitis	2.3e-05	0.000433	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—CD79A—ankylosing spondylitis	2.3e-05	0.000433	CbGpPWpGaD
Sorafenib—RAF1—Immune System—HLA-C—ankylosing spondylitis	2.29e-05	0.000432	CbGpPWpGaD
Sorafenib—RAF1—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	2.25e-05	0.000425	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—HLA-B—ankylosing spondylitis	2.23e-05	0.000421	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IL1RN—ankylosing spondylitis	2.23e-05	0.000421	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—PTGER4—ankylosing spondylitis	2.21e-05	0.000417	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—TLR4—ankylosing spondylitis	2.21e-05	0.000417	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—CD79A—ankylosing spondylitis	2.18e-05	0.000411	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—CD79A—ankylosing spondylitis	2.17e-05	0.00041	CbGpPWpGaD
Sorafenib—ABCB1—Allograft Rejection—TNF—ankylosing spondylitis	2.15e-05	0.000406	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—B3GNT2—ankylosing spondylitis	2.09e-05	0.000394	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—IL1A—ankylosing spondylitis	2.09e-05	0.000394	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—CD40LG—ankylosing spondylitis	2.08e-05	0.000392	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—B3GNT2—ankylosing spondylitis	2.07e-05	0.000391	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—HLA-A—ankylosing spondylitis	2.07e-05	0.00039	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—CRP—ankylosing spondylitis	2.06e-05	0.000388	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—PTGER4—ankylosing spondylitis	2.01e-05	0.000379	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—PTGER4—ankylosing spondylitis	2.01e-05	0.000378	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL1RN—ankylosing spondylitis	1.99e-05	0.000375	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—PTGER4—ankylosing spondylitis	1.99e-05	0.000375	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—HLA-B—ankylosing spondylitis	1.98e-05	0.000373	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—TLR4—ankylosing spondylitis	1.97e-05	0.000372	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—CD79A—ankylosing spondylitis	1.96e-05	0.000369	CbGpPWpGaD
Sorafenib—KIT—Immune System—IL1A—ankylosing spondylitis	1.88e-05	0.000355	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—IL1A—ankylosing spondylitis	1.88e-05	0.000355	CbGpPWpGaD
Sorafenib—KIT—Immune System—CD40LG—ankylosing spondylitis	1.87e-05	0.000353	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—CD40LG—ankylosing spondylitis	1.87e-05	0.000353	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—HLA-A—ankylosing spondylitis	1.83e-05	0.000345	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—PTGER4—ankylosing spondylitis	1.81e-05	0.000341	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—PTGER4—ankylosing spondylitis	1.81e-05	0.000341	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—IL1A—ankylosing spondylitis	1.79e-05	0.000337	CbGpPWpGaD
Sorafenib—KDR—Developmental Biology—TNF—ankylosing spondylitis	1.79e-05	0.000337	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—IL1A—ankylosing spondylitis	1.78e-05	0.000336	CbGpPWpGaD
Sorafenib—KIT—Immune System—HLA-B—ankylosing spondylitis	1.78e-05	0.000336	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—HLA-B—ankylosing spondylitis	1.78e-05	0.000336	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—CD40LG—ankylosing spondylitis	1.78e-05	0.000335	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—MMP3—ankylosing spondylitis	1.77e-05	0.000334	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—CD40LG—ankylosing spondylitis	1.77e-05	0.000334	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CD79A—ankylosing spondylitis	1.75e-05	0.000329	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—CRP—ankylosing spondylitis	1.75e-05	0.000329	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—PTGER4—ankylosing spondylitis	1.72e-05	0.000324	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—PTGER4—ankylosing spondylitis	1.71e-05	0.000323	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—MMP3—ankylosing spondylitis	1.7e-05	0.000321	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—HLA-B—ankylosing spondylitis	1.69e-05	0.000319	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—HLA-B—ankylosing spondylitis	1.69e-05	0.000318	CbGpPWpGaD
Sorafenib—BRAF—Disease—HLA-A—ankylosing spondylitis	1.67e-05	0.000316	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—TLR4—ankylosing spondylitis	1.67e-05	0.000316	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—MMP3—ankylosing spondylitis	1.66e-05	0.000313	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—MMP3—ankylosing spondylitis	1.66e-05	0.000313	CbGpPWpGaD
Sorafenib—KIT—Immune System—HLA-A—ankylosing spondylitis	1.65e-05	0.000311	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—HLA-A—ankylosing spondylitis	1.65e-05	0.000311	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IL1A—ankylosing spondylitis	1.61e-05	0.000303	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—CD40LG—ankylosing spondylitis	1.6e-05	0.000301	CbGpPWpGaD
Sorafenib—KIT—Immune System—CRP—ankylosing spondylitis	1.57e-05	0.000297	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—CRP—ankylosing spondylitis	1.57e-05	0.000297	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—HLA-A—ankylosing spondylitis	1.57e-05	0.000295	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—HLA-A—ankylosing spondylitis	1.56e-05	0.000295	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—PTGER4—ankylosing spondylitis	1.54e-05	0.000291	CbGpPWpGaD
Sorafenib—MAPK11—Developmental Biology—TNF—ankylosing spondylitis	1.54e-05	0.00029	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—B3GNT2—ankylosing spondylitis	1.53e-05	0.000289	CbGpPWpGaD
Sorafenib—KIT—Disease—HLA-A—ankylosing spondylitis	1.52e-05	0.000287	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—HLA-B—ankylosing spondylitis	1.52e-05	0.000286	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—TLR4—ankylosing spondylitis	1.51e-05	0.000285	CbGpPWpGaD
Sorafenib—KIT—Immune System—TLR4—ankylosing spondylitis	1.51e-05	0.000285	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—B3GNT2—ankylosing spondylitis	1.5e-05	0.000283	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—CRP—ankylosing spondylitis	1.49e-05	0.000282	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—CRP—ankylosing spondylitis	1.49e-05	0.000281	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—PTGER4—ankylosing spondylitis	1.47e-05	0.000277	CbGpPWpGaD
Sorafenib—FGFR1—Disease—HLA-A—ankylosing spondylitis	1.45e-05	0.000273	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—HLA-A—ankylosing spondylitis	1.44e-05	0.000272	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—TLR4—ankylosing spondylitis	1.43e-05	0.00027	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL1A—ankylosing spondylitis	1.43e-05	0.00027	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—MMP3—ankylosing spondylitis	1.43e-05	0.00027	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—TLR4—ankylosing spondylitis	1.43e-05	0.000269	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—MMP3—ankylosing spondylitis	1.43e-05	0.000269	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CD40LG—ankylosing spondylitis	1.42e-05	0.000268	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—MMP3—ankylosing spondylitis	1.42e-05	0.000267	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—HLA-A—ankylosing spondylitis	1.41e-05	0.000265	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—PTGER4—ankylosing spondylitis	1.38e-05	0.000259	CbGpPWpGaD
Sorafenib—RAF1—Immune System—HLA-B—ankylosing spondylitis	1.35e-05	0.000255	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—CRP—ankylosing spondylitis	1.34e-05	0.000253	CbGpPWpGaD
Sorafenib—FGFR1—Developmental Biology—TNF—ankylosing spondylitis	1.32e-05	0.000248	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—HLA-A—ankylosing spondylitis	1.3e-05	0.000245	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—B3GNT2—ankylosing spondylitis	1.3e-05	0.000245	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MMP3—ankylosing spondylitis	1.29e-05	0.000243	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MMP3—ankylosing spondylitis	1.29e-05	0.000243	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—TLR4—ankylosing spondylitis	1.29e-05	0.000243	CbGpPWpGaD
Sorafenib—RAF1—Immune System—HLA-A—ankylosing spondylitis	1.25e-05	0.000237	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MMP3—ankylosing spondylitis	1.22e-05	0.00023	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MMP3—ankylosing spondylitis	1.22e-05	0.00023	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CRP—ankylosing spondylitis	1.2e-05	0.000226	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PTGER4—ankylosing spondylitis	1.19e-05	0.000224	CbGpPWpGaD
Sorafenib—RAF1—Disease—HLA-A—ankylosing spondylitis	1.16e-05	0.000218	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—B3GNT2—ankylosing spondylitis	1.16e-05	0.000218	CbGpPWpGaD
Sorafenib—RAF1—Immune System—TLR4—ankylosing spondylitis	1.15e-05	0.000216	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—B3GNT2—ankylosing spondylitis	1.13e-05	0.000213	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MMP3—ankylosing spondylitis	1.1e-05	0.000207	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—B3GNT2—ankylosing spondylitis	1.07e-05	0.000201	CbGpPWpGaD
Sorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	1.06e-05	0.0002	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—B3GNT2—ankylosing spondylitis	1.06e-05	0.000199	CbGpPWpGaD
Sorafenib—RAF1—Developmental Biology—TNF—ankylosing spondylitis	1.05e-05	0.000199	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MMP3—ankylosing spondylitis	1.05e-05	0.000198	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MMP3—ankylosing spondylitis	9.79e-06	0.000185	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—B3GNT2—ankylosing spondylitis	9.03e-06	0.00017	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MMP3—ankylosing spondylitis	8.45e-06	0.000159	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—B3GNT2—ankylosing spondylitis	6.97e-06	0.000131	CbGpPWpGaD
